Perils and pitfalls of long-term effects of proton pump inhibitors

References

• Wallace JL, Sharkey KA. Pharmacotherapy of gastric acidity, peptic ulcers, and gastroesophageal reflux disease. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics (12th Edition). Chabner BA, Brunton LL, Knollman BC (Eds). McGraw-Hill, New York, NY, USA (2011).
   Google Scholar
• Theodorou A, Johnson K, Szychowski J. Proton pump inhibitor drug utilization and cost trends. Am. J. Pharm. Benefits 2(5), 327–330 (2010).
   Google Scholar
• Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol. Res. 59(3), 135–153 (2009).
   PubMed Web of Science ®Google Scholar
• Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology 139(4), 1115–1127 (2010).
   PubMed Web of Science ®Google Scholar
• Baker DE. Intravenous proton pump inhibitors. Rev. Gastroenterol. Disord. 6(1), 22–34 (2006).
   PubMedGoogle Scholar
• Bardou M, Martin J, Barkun A. Intravenous proton pump inhibitors: an evidence-based review of their use in gastrointestinal disorders. Drugs 69(4), 435–448 (2009).
   PubMed Web of Science ®Google Scholar
• Berardi RR, Welage LS. Proton-pump inhibitors in acid-related diseases. Am. J. Health. Syst. Pharm. 55(21), 2289–2298 (1998).
   PubMedGoogle Scholar
• Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur. J. Clin. Pharmacol. 66(12), 1265–1271 (2010).
   PubMedGoogle Scholar
• Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad. Med. J. 83(975), 66–68 (2007).
   PubMed Web of Science ®Google Scholar
• Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm. World Sci. 28(4), 189–193 (2006).
   PubMedGoogle Scholar
• Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J. Clin. Pharm. Ther. 25(5), 333–340 (2000).
   PubMed Web of Science ®Google Scholar
• Härmark L, van der Wiel HE, de Groot MC, van Grootheest AC. Proton pump inhibitor-induced acute interstitial nephritis. Br. J. Clin. Pharmacol. 64(6), 819–823 (2007).
   PubMed Web of Science ®Google Scholar
• Christensen KL, Holman RC, Steiner CA, Sejvar JJ, Stoll BJ, Schonberger LB. Infectious disease hospitalizations in the United States. Clin. Infect. Dis. 49(7), 1025–1035 (2009).
   PubMed Web of Science ®Google Scholar
• Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev. Clin. Pharmacol. 5(3), 337–344 (2012).
   PubMed Web of Science ®Google Scholar
• Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment. Pharmacol. Ther. 31(11), 1165–1177 (2010).
   PubMed Web of Science ®Google Scholar
• Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 183(3), 310–319 (2011).
   PubMed Web of Science ®Google Scholar
• Hermos JA, Young MM, Fonda JR, Gagnon DR, Fiore LD, Lawler EV. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin. Infect. Dis. 54(1), 33–42 (2012).
   PubMed Web of Science ®Google Scholar
• Canani RB, Cirillo P, Roggero P et al.; Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 117(5), e817–e820 (2006).
   PubMed Web of Science ®Google Scholar
• McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353(23), 2433–2441 (2005).
   PubMed Web of Science ®Google Scholar
• Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment. Pharmacol. Ther. 23(1), 3–10 (2006).
   PubMed Web of Science ®Google Scholar
• Deshpande A, Pant C, Pasupuleti V et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin. Gastroenterol. Hepatol. 10(3), 225–233 (2012).
   PubMed Web of Science ®Google Scholar
• Howell MD, Novack V, Grgurich P et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med. 170(9), 784–790 (2010).
   PubMed Web of Science ®Google Scholar
• Sipponen P, Härkönen M. Hypochlorhydric stomach: a risk condition for calcium malabsorption and osteoporosis? Scand. J. Gastroenterol. 45(2), 133–138 (2010).
   PubMed Web of Science ®Google Scholar
• Wright MJ, Proctor DD, Insogna KL, Kerstetter JE. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr. Rev. 66(2), 103–108 (2008).
   PubMed Web of Science ®Google Scholar
• O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am. J. Med. 118(7), 778–781 (2005).
   PubMed Web of Science ®Google Scholar
• McGowan B, Bennett K, Barry M. Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice. Pharmacoepidemiol. Drug Saf. 19(7), 763–769 (2010).
   Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif. Tissue Int. 79(2), 76–83 (2006).
   PubMed Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24), 2947–2953 (2006).
   PubMed Web of Science ®Google Scholar
• Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179(4), 319–326 (2008).
   PubMed Web of Science ®Google Scholar
• Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28(8), 951–959 (2008).
   PubMed Web of Science ®Google Scholar
• Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 139(1), 93–101 (2010).
   PubMed Web of Science ®Google Scholar
• Yu EW, Blackwell T, Ensrud KE et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif. Tissue Int. 83(4), 251–259 (2008).
   PubMed Web of Science ®Google Scholar
• Gray SL, LaCroix AZ, Larson J et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch. Intern. Med. 170(9), 765–771 (2010).
   PubMed Web of Science ®Google Scholar
• Khalili H, Huang ES, Jacobson BC, Camargo CA Jr, Feskanich D, Chan AT. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 344, e372 (2012).
   PubMed Web of Science ®Google Scholar
• Roux C, Briot K, Gossec L et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif. Tissue Int. 84(1), 13–19 (2009).
   PubMed Web of Science ®Google Scholar
• Eom CS, Park SM, Myung SK, Yun JM, Ahn JS. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann. Fam. Med. 9(3), 257–267 (2011).
   PubMed Web of Science ®Google Scholar
• Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am. J. Gastroenterol. 106(7), 1209–18; quiz 1219 (2011).
   PubMed Web of Science ®Google Scholar
• Ye X, Liu H, Wu C et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 23(9), 794–800 (2011).
   PubMed Web of Science ®Google Scholar
• Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am. J. Med. 124(6), 519–526 (2011).
   PubMed Web of Science ®Google Scholar
• US FDA. US FDA Drug Safety Communication: possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. (2011).
   Google Scholar
• Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N. Engl. J. Med. 355(17), 1834–1836 (2006).
   PubMed Web of Science ®Google Scholar
• Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin. Endocrinol. (Oxf) 69(2), 338–341 (2008).
   PubMed Web of Science ®Google Scholar
• Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr. Opin. Gastroenterol. 27(2), 180–185 (2011).
   Google Scholar
• Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW. Omeprazole and refractory hypomagnesaemia. BMJ 337, a425 (2008).
   PubMed Web of Science ®Google Scholar
• Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW. Hypomagnesemia induced by several proton-pump inhibitors. Ann. Intern. Med. 151(10), 755–756 (2009).
   PubMed Web of Science ®Google Scholar
• Furlanetto TW, Faulhaber GA. Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg. Arch. Intern. Med. 171(15), 1391–1392 (2011).
   PubMed Web of Science ®Google Scholar
• Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. A case series of proton pump inhibitor-induced hypomagnesemia. Am. J. Kidney Dis. 56(1), 112–116 (2010).
   PubMed Web of Science ®Google Scholar
• Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors–a review. Neth. J. Med. 67(5), 169–172 (2009).
   PubMed Web of Science ®Google Scholar
• Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 103(6), 387–395 (2010).
   PubMed Web of Science ®Google Scholar
• Quasdorff M, Mertens J, Dinter J, Steffen HM. Recurrent hypomagnesemia with proton-pump inhibitor rechallenge. Ann. Intern. Med. 155(6), 405–407 (2011).
   PubMed Web of Science ®Google Scholar
• Regolisti G, Cabassi A, Parenti E, Maggiore U, Fiaccadori E. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am. J. Kidney Dis. 56(1), 168–174 (2010).
   PubMed Web of Science ®Google Scholar
• Metz DC, Sostek MB, Ruszniewski P, Forsmark CE, Monyak J, Pisegna JR. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am. J. Gastroenterol. 102(12), 2648–2654 (2007).
   PubMed Web of Science ®Google Scholar
• Gau JT, Yang YX, Chen R, Kao TC. Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol. Drug Saf. 21(5), 553–559 (2012).
   PubMed Web of Science ®Google Scholar
• US FDA. US FDA Drug Safety Communication: low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). (2011).
   Google Scholar
• Zlabek JA, Anderson CG. Lansoprazole-induced thrombocytopenia. Ann. Pharmacother. 36(5), 809–811 (2002).
   PubMed Web of Science ®Google Scholar
• Watson TD, Stark JE, Vesta KS. Pantoprazole-induced thrombocytopenia. Ann. Pharmacother. 40(4), 758–761 (2006).
   PubMed Web of Science ®Google Scholar
• Miller JL, Gormley AK, Johnson PN. Pantoprazole-induced thrombocytopenia. Indian J. Pediatr. 76(12), 1278–1279 (2009).
   PubMed Web of Science ®Google Scholar
• Dotan E, Katz R, Bratcher J et al. The prevalence of pantoprozole associated thrombocytopenia in a community hospital. Expert Opin. Pharmacother. 8(13), 2025–2028 (2007).
   PubMed Web of Science ®Google Scholar
• Conrad M. Iron absorption. In: Physiology of the Gastrointestinal Tract, 2nd Edition. Johnson LR, Christensen J (Eds). Raven Press, NY, USA (1987).
   Google Scholar
• Jacobs P, Bothwell T, Charlton RW. Role of hydrochloric acid in iron absorption. J. Appl. Physiol. 19, 187–188 (1964).
   PubMed Web of Science ®Google Scholar
• Schade SG, Cohen RJ, Conrad ME. Effect of hydrochloric acid on iron absorption. N. Engl. J. Med. 279(13), 672–674 (1968).
   PubMed Web of Science ®Google Scholar
• Stewart CA, Termanini B, Sutliff VE et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment. Pharmacol. Ther. 12(1), 83–98 (1998).
   PubMed Web of Science ®Google Scholar
• Skikne BS, Lynch SR, Cook JD. Role of gastric acid in food iron absorption. Gastroenterology 81(6), 1068–1071 (1981).
   PubMed Web of Science ®Google Scholar
• Khatib MA, Rahim O, Kania R, Molloy P. Iron deficiency anemia: induced by long-term ingestion of omeprazole. Dig. Dis. Sci. 47(11), 2596–2597 (2002).
   Google Scholar
• Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South. Med. J. 97(9), 887–889 (2004).
   PubMed Web of Science ®Google Scholar
• Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J. Clin. Gastroenterol. 14(4), 288–292 (1992).
   PubMed Web of Science ®Google Scholar
• Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 56(9), 1291–1295 (2007).
   PubMed Web of Science ®Google Scholar
• Neale G. B12 binding proteins. Gut 31(1), 59–63 (1990).
   PubMed Web of Science ®Google Scholar
• Kittang E, Aadland E, Schjønsby H, Røhss K. The effect of omeprazole on gastric acidity and the absorption of liver cobalamins. Scand. J. Gastroenterol. 22(2), 156–160 (1987).
   PubMed Web of Science ®Google Scholar
• Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann. Intern. Med. 120(3), 211–215 (1994).
   PubMed Web of Science ®Google Scholar
• Lavy NW. Omeprazole and vitamin B12. Ann. Intern. Med. 121(1), 74 (1994).
   Google Scholar
• Termanini B, Gibril F, Sutliff VE, Yu F, Venzon DJ, Jensen RT. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am. J. Med. 104(5), 422–430 (1998).
   PubMed Web of Science ®Google Scholar
• Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment. Pharmacol. Ther. 27(11), 1110–1121 (2008).
   PubMed Web of Science ®Google Scholar
• Rozgony NR, Fang C, Kuczmarski MF, Bob H. Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial? J. Nutr. Elder. 29(1), 87–99 (2010).
   PubMedGoogle Scholar
• Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig. Dis. Sci. 53(2), 385–393 (2008).
   PubMed Web of Science ®Google Scholar
• den Elzen WP, Groeneveld Y, de Ruijter W et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment. Pharmacol. Ther. 27(6), 491–497 (2008).
   PubMed Web of Science ®Google Scholar
• Huerta-Alardín AL, Varon J, Marik PE. Bench-to-bedside review: rhabdomyolysis – an overview for clinicians. Crit. Care 9(2), 158–169 (2005).
   PubMed Web of Science ®Google Scholar
• Yusoff IF, Nairn P, Morgan CA. Multiple organ failure related to pantoprazole. Aust. N. Z. J. Med. 29(6), 833–834 (1999).
   Google Scholar
• Dehesa C, Kassel G. Multiple organ failure and pantoprazole. Aust. N. Z. J. Med. 30(6), 730 (2000).
   Google Scholar
• Nozaki M, Suzuki T, Hirano M. Rhabdomyolysis associated with omeprazole. J. Gastroenterol. 39(1), 86 (2004).
   Google Scholar
• Tröger U, Reiche I, Jepsen MS, Huth C, Bode-Böger SM. Esomeprazole-induced rhabdomyolysis in a patient with heart failure. Intensive Care Med. 36(7), 1278–1279 (2010).
   Google Scholar
• Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur. J. Clin. Pharmacol. 62(6), 473–479 (2006).
   PubMed Web of Science ®Google Scholar
• Ruffenach SJ, Siskind MS, Lien YH. Acute interstitial nephritis due to omeprazole. Am. J. Med. 93(4), 472–473 (1992).
   PubMedGoogle Scholar
• Geevasinga N, Kairaitis L, Rangan GK, Coleman PL. Acute interstitial nephritis secondary to esomeprazole. Med. J. Aust. 182(5), 235–236 (2005).
   Google Scholar
• Krishnamurthy M, Snyder R, Bachurina M. Long-term use of proton pump inhibitors: are they really safe? A case of delayed acute interstitial nephritis. J. Am. Geriatr. Soc. 57(8), 1513–1514 (2009).
   Google Scholar
• Ra A, Tobe SW. Acute interstitial nephritis due to pantoprazole. Ann. Pharmacother. 38(1), 41–45 (2004).
   PubMed Web of Science ®Google Scholar
• Ricketson J, Kimel G, Spence J, Weir R. Acute allergic interstitial nephritis after use of pantoprazole. CMAJ 180(5), 535–538 (2009).
   Google Scholar
• Moore I, Sayer JA, Nayar A, Ahmed S, Tapson JS. Pantoprazole-induced acute interstitial nephritis. J. Nephrol. 17(4), 580–581 (2004).
   Google Scholar
• Geevasinga N, Coleman PL, Roger SD. Rabeprazole-induced acute interstitial nephritis. Nephrology (Carlton) 10(1), 7–9 (2005).
   Google Scholar
• Jose J, Saravu K, Khera K, Jimmy B, Shastry BA. Acute interstitial nephritis related to lansoprazole administration. J. Pak. Med. Assoc. 58(4), 206–207 (2008).
   Google Scholar
• Kim MJ, Heim M, Mayr M. Effect of corticosteroids during ongoing drug exposure in pantoprazole-induced interstitial nephritis. Nephrol. Dial. Transplant. 25(5), 1716–1719 (2010).
   Google Scholar
• Simpson IJ, Marshall MR, Pilmore H et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton) 11(5), 381–385 (2006).
   PubMed Web of Science ®Google Scholar
• Sierra F, Suarez M, Rey M, Vela MF. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment. Pharmacol. Ther. 26(4), 545–553 (2007).
   PubMed Web of Science ®Google Scholar
• Torpey N, Barker T, Ross C. Drug-induced tubulo-interstitial nephritis secondary to proton pump inhibitors: experience from a single UK renal unit. Nephrol. Dial. Transplant. 19(6), 1441–1446 (2004).
   Google Scholar
• Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. Clin. Gastroenterol. Hepatol. 4(5), 597–604 (2006).
   PubMed Web of Science ®Google Scholar